Objectives: Pandemic H1N1/09 viruses with the neuraminidase H274Y mutation have emerged in untreated patients or following oseltamivir therapy or prophylaxis. There have been no reports yet of zanamivir-resistant H1N1/09 viruses in previously healthy patients. We wanted to determine whether we could select for neuraminidase mutations conferring high-level resistance to zanamivir by in vitro passage of the virus. We also wanted to investigate if passaging in a combination of zanamivir and oseltamivir could prevent the emergence of the H274Y mutation.
Introduction
The influenza neuraminidase inhibitors (NAIs) oseltamivir (Tamiflu) and zanamivir (Relenza) have been licensed for more than 10 years. Differences in chemical structures result in the two drugs binding differently within the active site of the influenza neuraminidase (NA). Due to the similarity of zanamivir to the natural ligand, it binds without any structural changes. Conversely, the presence of a hydrophobic side chain in oseltamivir means structural rearrangements are necessary for it to bind with high affinity. 1, 2 The E276 in the NA active site rotates to form a salt link with R224, creating the hydrophobic pocket necessary to accommodate the side chain of oseltamivir. (Note that all numbering of NA amino acids is based on N2 numbering.) Peramivir has recently been licensed in Japan and South Korea and has similarities in chemical structure to both oseltamivir and zanamivir. Like oseltamivir, it has a hydrophobic side chain, and hence it also requires similar structural rearrangements for its high-affinity binding. 3 We first predicted back in 1998 that these structural arrangements would be more likely to lead to the development of resistance to oseltamivir. 1 The global spread of the oseltamivir-resistant seasonal H1N1 strain with an H274Y mutation in 2007-08 confirmed this prediction, and demonstrated that drug-resistant viruses could still be fit and transmissible. 4, 5 With the emergence and rapid global spread of the pandemic H1N1/09 virus, the use of oseltamivir was implemented in some countries to mitigate the impact of this new strain. However, the development of oseltamivir resistance was a concern with increased drug use. Isolation of resistant viruses from immunocompromised patients was not unexpected due to the prolonged therapy, 6 -11 but there were also early reports of detection and spread of oseltamivirresistant virus among untreated patients. 12, 13 Peramivir is being developed as an alternative in the event of failure of oseltamivir therapy; however, the H274Y mutation can also confer clinically significant cross-resistance to peramivir. 10 The H274Y viruses remain susceptible to zanamivir.
In addition to the H274Y mutation there have also been reports of mutations at residue I222 (I223 N1 numbering) in H1N1/09 isolates, which can reduce susceptibility to all NAIs. A virus with a single I222R mutation arose after sequential oseltamivir and zanamivir treatment of an immunocompromised patient.
14 This conferred reduced susceptibility to oseltamivir, zanamivir and peramivir with 45-, 10-and 7-fold reductions, respectively, in susceptibility in the NA enzyme inhibition assay. An I222V mutation was also reported to have arisen in conjunction with H274Y, but no virus was available for susceptibility testing. 13 A third report described the emergence of a virus with both H274Y and I222R mutations after oseltamivir treatment 15 and a single I222K mutation in another isolate. The dual mutation further increased resistance by 10-to 90-fold over the H274Y mutation alone to around 10000 nM for both oseltamivir and peramivir. While this mutation also reduced susceptibility to zanamivir by 10-fold compared with the single H274Y mutant, the IC 50 s were still ,10 nM. Hence there is no report yet of high-level resistance occurring to zanamivir in a previously healthy patient.
We were therefore interested to determine whether high-level resistance to zanamivir could be generated by serially passaging a pandemic H1N1/09 virus in vitro. Furthermore, since we had already seen that H274Y could emerge in the pandemic H1N1/ 09 virus, we wanted to investigate whether passaging in a combination of zanamivir and oseltamivir could prevent the emergence of the H274Y mutation. It has recently been demonstrated that dual treatment with oseltamivir and peramivir during influenza pandemic H1N1/09 virus infections in vitro and in mice could produce additive to synergistic responses. 16 In a clinical trial in which the predominant strain was an H3N2 virus, a combination of oseltamivir and zanamivir in adults appeared less effective than oseltamivir monotherapy, and not significantly more effective than zanamivir monotherapy. 17 However, neither study investigated if dual NAI treatment could reduce selection of resistant viruses.
Our results demonstrated that we were not able to generate a variant with an NA mutation conferring high-level resistance to zanamivir. In addition, viruses passaged in the combination of oseltamivir and zanamivir initially acquired a D198G mutation in the NA, which reduced susceptibility to zanamivir, oseltamivir and peramivir by several fold. However, further passaging selected for a virus with both D198G and H274Y mutations, which acted synergistically, conferring extremely high levels of resistance to both oseltamivir and peramivir.
Materials and methods

Viruses and cell culture
Madin-Darby Canine Kidney (MDCK) cells were grown in DMEM/F12 medium (Life Technologies, Australia) with 7.5% fetal bovine serum, glutamine and antibiotics. For plaque assays the overlay was DMEM/ F12 without serum with 0.5% immunodiffusion-grade agarose (MP Biomedicals, Australia), with the addition of 1 mg/mL L-1-tosylamido-2-phenylethyl chloromethyl ketone ('TPCK')-treated trypsin (Worthington, USA). For plaque reduction assays (PRAs), inhibitors were incorporated into the overlay with final concentrations ranging from 0.01 nM to 10 mM. Plaque assays were fixed with 1% formalin, the agarose was removed and cells were stained with 0.05% neutral red. For growth curves, MDCK cells in a 24-well dish were infected with a multiplicity of infection of 1.0. Two wells were harvested every 8 h, and each sample was titrated in a plaque assay in MDCK cells.
We used an egg-cultured H1N1/09 pandemic influenza virus (A/Swine/ Shepparton/6/2009) for passaging [GenBank haemagglutinin (HA) JQ273542 and NA JQ273543]. The original sample for this virus was submitted by the Department of Primary Industries, Victoria, Australia, to the CSIRO, Australian Animal Health Laboratory, Diagnostic, Surveillance and Response (DSR) group where the virus was cultured. 18 The seasonal A/Mississippi/03/01 wild-type and H274Y mutant were used as reference controls. 19 
Passaging of viruses
The virus was passaged in 24-well culture dishes of MDCK cells. Two sets of passaging were carried out in parallel. The first set was in the presence of increasing zanamivir (Z) concentrations, starting at 1 nM and gradually increasing at each passage (P) to 1 mM at P12. The second set was passaged in both zanamivir and oseltamivir (ZO), starting at 1 nM for each, increasing both drug concentrations at each passage, until the zanamivir reached 10 nM ( 10 times the IC 50 in the PRA) at P5. Since we were investigating whether we could prevent the emergence of the H274Y mutation we wanted greater selection pressure with oseltamivir, hence zanamivir was maintained at 10 nM with the oseltamivir increasing to 1 mM by P12. Serial 10-fold dilutions of passaged virus were inoculated into five rows. After adsorption the inoculum was removed from one of the five rows and the cells were washed to remove any residual inhibitor. This row was used to compare relative growth of virus without inhibitor with the same inoculum in the other wells with inhibitor. Virus that grew in these wells was also used for NAI assays. Two different drug concentrations were added to the remaining four rows, without removal of the inoculum. Virus was harvested for passaging from the wells that grew from the most dilute inoculum from either drug concentration. The starting virus was also passaged in the absence of any inhibitors for detecting any mutations resulting from adaptation to growth in MDCK cells.
Chemicals and inhibitors
Zanamivir and peramivir were provided by GlaxoSmithKline (Stevenage, UK). Oseltamivir carboxylate was kindly provided by Dr Keith Watson (Walter and Eliza Hall Institute, Australia). Inhibitors were diluted in water, with dilutions ranging from 0.001 to 100000 nM. The fluorescent substrate 4-methylumbelliferyl N-acetyl-a-D-neuraminic acid (MUNANA) was obtained from Carbosynth (UK).
Haemagglutination elution assays
In order to screen for possible HA mutations resulting in decreased affinity for receptors, we carried out HA elution (HAE) assays at each passage. 20 Serial 2-fold dilutions of virus were prepared in 25 mL of PBS in round-bottomed 96-well plates to which 50 mL of a 0.5% suspension of chicken red blood cells (RBCs) was added, and the plates were incubated at 48C for 1 h. Agglutination was recorded, then plates were incubated at 378C. Elution was monitored hourly for up to 6 h to determine whether passaged viruses eluted more rapidly than the control, suggesting an HA mutation resulting in decreased receptor binding affinity may have emerged. After plaque purification of the passaged viruses, elution
In vitro selection of resistant H1N1/09 viruses from both chicken and turkey RBCs was compared to determine whether there were any differences in HA receptor specificity and affinity.
A modified HAE assay carried out in the presence of NAIs can be used to determine the effects of either an NA or HA mutation. A concentration of each virus capable of elution was pre-incubated with serial 2-fold dilutions of zanamivir or oseltamivir ranging from 10 mM to 10 nM, prior to the addition of RBCs. Plates were incubated at 48C for 1 h to allow agglutination to occur, and were then incubated at 378C to determine what concentration of inhibitor prevented elution.
Enzyme assays
We used an endpoint MUNANA-based fluorescent assay 21 for measuring drug susceptibility at each passage, and IC 50 kinetics were carried out on plaque-purified isolates. 19, 22 Final concentrations in the assay were 50 mM sodium acetate pH 5.5, 5 mM CaCl 2 and 100 mM MUNANA. Fluorescence was measured in a BMG FLUOstar Optima reader with 355 nM excitation and 460 nM emission filters. The endpoint assay had a 30 min pre-incubation of virus and inhibitors, then after incubation with MUNANA for 60 min the reaction was stopped by the addition of Na 2 CO 3 . The IC 50 kinetics use two separate assays to determine whether the inhibitors are fast or slow binding. One assay has a 30 min pre-incubation of virus and inhibitor prior to the addition of substrate. The second method has the simultaneous addition of virus, inhibitors and MUNANA. Fluorescence for both assays was monitored at 1 min intervals for 60 min to ensure a stable signal. The IC 50 was calculated as the concentration of inhibitor resulting in a 50% reduction in fluorescent units ('FUs') compared with the control. IC 50 s were calculated for each 10 min interval, and were then plotted as bar graphs for both assays.
Enzyme kinetics
To calculate the Michaelis-Menten constant, K m , the rate of hydrolysis of MUNANA was measured at substrate concentrations ranging from 6.25 to 800 mM, depending on the virus. At least five independent assays were carried out. The K m was calculated using a non-linear regression function in GraphPad Prism. The K i values from duplicate samples were calculated using non-linear regression and one-site competitive binding in GraphPad Prism, as previously described. 19 Since we have previously shown that the K i s also change with time due to the slow binding of the inhibitors, we used the rates for the 50-60 min time period, since these were the closest to a steady state.
Sequencing of isolates
Sequencing was conducted on plaque-purified viruses from the zanamivir ZP6, zanamivir and oseltamivir ZOP4 and ZOP12, and the control P12. Viral RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Germany). The viral HA and NA were amplified with SuperScript One-Step RT-PCR (Invitrogen, USA) by gene-specific primers (sequences available upon request). The amplicons were gel purified (QIAquick, Qiagen) and sequenced by the AAHL DSR Sequencing Laboratory (CSIRO, Australia).
Results
Passaging of viruses
The wild-type virus was initially screened in a PRA and some inhibition was observed with both zanamivir and oseltamivir at 1 nM, with only pinpoint plaques visible at 10 nM ( Figure 1 ). Hence passaging was commenced at 1 nM. After six passages in zanamivir, at 20 nM, the virus (ZP6) was eluting more rapidly in the HAE assay, and there was a subtle increase in IC 50 of around 2-fold in the NA enzyme inhibition assay. These phenotypes did not change for the remaining passaging. From P9 to P12 growth of the virus was severely inhibited, and by P12 in 1 mM zanamivir we were unable to rescue any infectious virus. Sequence analysis of ZP6 virus revealed an HA mutation G158E (H3 numbering or G155E H1 numbering) and an NA mutation N146S (N2 numbering) both of which were retained from P6 through to P11. Plaque purification of ZP6 did not identify any progeny with only a single NA or HA mutation. We did not plaque purify any isolates from the earlier passages as they did not show any phenotypic changes so we do not know if the mutations co-evolved.
For the ZO passaged virus after P4 (ZOP4 virus), with zanamivir and oseltamivir around 4 nM, there was an increase in IC 50 for both inhibitors in the NA enzyme inhibition assay, but there was no difference in the HAE assay. Sequencing revealed a D198G mutation in the NA, but none in the HA, consistent with the HAE assay. This phenotype was retained until P11 when a larger increase in IC 50 was observed for oseltamivir, but not for zanamivir, and an even greater increase by P12 suggesting a highly resistant mutant (ZOP12) had outgrown the ZOP4-like virus. Sequencing revealed an H274Y mutation in the NA in addition to the D198G mutation. No mutations or phenotypic changes were detected in the control passaged virus after 12 passages. Plaques were picked and amplified from each of the phenotypes for further characterization.
Enzyme inhibition assays
The NAIs are known to be time dependent or slow binding inhibitors. 23 -26 This means that pre-incubation of the inhibitor with the NA in the absence of substrate should increase the percentage of sites occupied by the inhibitor, and thus lead to a lower IC 50 . In contrast, if the inhibitor is fast binding, then the inhibitor will quickly reach equilibrium, so that pre-incubation has minimal effect on the IC 50 . Many of the mutations resulting in decreased binding of the NAIs also lead to loss of slow binding. 22,23,27 -29 It has been hypothesized that the slow binding of zanamivir is due to the need for displacement of a water molecule before the guanidinium group can bind 25 and for the rotation of the E276 1 for oseltamivir and peramivir to bind. However, we have also recently shown that a D198E mutation leads to loss of slow binding of all inhibitors. 22 Hence the slow binding phenotype is not solely due to the previously proposed structural changes.
As a simple way of evaluating the fast or slow binding phenotype we have recently developed a modified IC 50 kinetics drug inhibition assay, to monitor the changes in drug binding in real time. 19 We compared the changes in IC 50 over 60 min in one assay without pre-incubation with inhibitor to changes in IC 50 in a second assay with pre-incubation with inhibitors. The slow binding phenotype showed a decrease in IC 50 over time with no pre-incubation, and a lower initial IC 50 with pre-incubation. We also saw some apparent dissociation of inhibitors after preincubation, as the IC 50 s increased during the 60 min reaction. We evaluated this assay using a number of wild-type and mutant viruses and the results we obtained were consistent with previous reports of slow binding to wild-type NAs and loss of slow binding to mutant NAs. 19 McKimm-Breschkin et al.
We used the single endpoint IC 50 assay for screening for possible changes in IC 50 to zanamivir and oseltamivir during passaging. We used our IC 50 kinetics assay on the plaque-purified isolates to determine whether mutations impacted on the rate of inhibitor binding or apparent dissociation of zanamivir, oseltamivir and peramivir. 19, 22 Titrations of the NA enzyme activity of the four virus stocks demonstrated that the ZOP12 NA had significantly lower NA activity, despite having a comparable titre in the HA assay (data not shown). Final 60 min IC 50 s for the pre-incubated reaction are shown in Table 1 and graphs for both IC 50 kinetics reactions are shown in Figure 2 to demonstrate differences seen in the binding kinetics.
The plaque-purified ZP6 virus with an N146S NA mutation had around a 2-fold increase in IC 50 for both zanamivir and Figure 1 . Drug susceptibility of plaque-purified wild-type and mutant viruses in a PRA. MDCK cells were infected with each virus and were overlaid with increasing concentrations of zanamivir (Zan) or oseltamivir (Osel). Control and zanamivir passage 6, ZP6 (NA N146S and HA G158E) were fixed at day 4. Zanamivir+oseltamivir passage 4 virus (ZOP4; NA D198G) and zanamivir+oseltamivir passage 12 virus (ZOP12; NA D198G and H274Y) were fixed at day 6. The relative drug susceptibility is based on the drug concentration causing a 50% reduction in plaque size compared with the zero drug control. While all mutants demonstrated reduced susceptibility to both inhibitors, ZP6 also displayed a drug-dependent (Drug dept) phenotype, with either Zan or Osel, with more plaques in 1 and 10 nM inhibitor than in the control wells. The additional H274Y mutation in ZOP12 increased resistance over the single ZOP4 D198G, but only to oseltamivir.
In vitro selection of resistant H1N1/09 viruses 1877 JAC oseltamivir, but not for peramivir. The N146S mutation also had a subtle effect on the IC 50 kinetics, with a greater change in IC 50 over the 60 min in the pre-incubation reaction (+) for zanamivir compared with the wild-type virus. The change in the IC 50 over the 60 min for oseltamivir was faster for both the wild-type and ZP6 virus compared with zanamivir, which we have previously observed with oseltamivir in other viruses. 19 There was no difference in the peramivir kinetics, consistent with no detectable difference in IC 50 from the wild-type.
For the plaque-purified ZOP4 virus the D198G NA mutation conferred reduced susceptibility to all three NAIs of around 10-fold (Table 1) . Compared with the control virus there was faster binding over the 60 min in the no pre-incubation (2) reaction and faster apparent dissociation in the pre-incubation (+) reactions for both peramivir and zanamivir. The IC 50 s were still lower for both drugs with pre-incubation, hence they still demonstrated some slow binding, but not as slow as the wildtype virus. In contrast the oseltamivir IC 50 s were similar with or without pre-incubation, indicating complete loss of slow binding.
For the plaque-purified ZOP12 virus with D198G and H274Y mutations there was no difference in the zanamivir kinetics compared with the ZOP4 virus. However, this virus had extremely high IC 50 50 over the 60 min in the reaction without pre-incubation (2) as more inhibitor binds. Additionally, pre-incubation with drug enhances binding so that a lower initial IC 50 is seen in the (+) reaction compared with the (2) reaction (e.g. Con and ZP6 with zanamivir and peramivir). If NAs have lost slow binding, the pre-incubation does not enhance inhibitor binding, hence similar IC 50 s are seen in both assays (ZOP4 with oseltamivir, and ZOP12 with both oseltamivir and peramivir). Intermediate effects with faster binding and faster apparent dissociation, but still some enhancement with pre-incubation, is seen for ZOP4 and ZOP12 with zanamivir and ZOP4 with peramivir. Con, control passage virus; ZP6, zanamivir passage 6 virus; ZOP4, zanamivir +oseltamivir passage 4 virus; ZOP12, zanamivir+oseltamivir passage 12 virus. McKimm-Breschkin et al.
H1N1 virus wild-type and H274Y mutant, the D198 mutation enhanced resistance significantly over that caused by the H274Y mutation alone ( Table 1) .
Effect of mutations on RBC binding and elution
The ZP6 virus grew in concentrations of zanamivir up to 500 nM by P10, but the NA N146S mutation only conferred a 2-fold reduction in susceptibility in the NA enzyme inhibition assay. HA mutations resulting in decreased affinity for cell receptors, can also decrease drug susceptibility in vitro, since the virus is less dependent on the NA for elution. 30 Hence this suggested that it was the HA mutation facilitating growth through reduced affinity or altered specificity for the cell receptors. 20, 30 We evaluated all plaque-purified viruses in an HAE assay using either chicken or turkey RBCs. The standard HAE assay after initial agglutination at 48C monitors the rate of elution of virus at 378C. Elution is due to NA cleavage of sialic acids on the red cell receptors, and/or due to thermal dissociation of the HA. If a mutant virus elutes more rapidly than the wild-type it suggests a weaker HA affinity. If a mutant elutes poorly this is most likely due to decreased NA activity rather than increased HA affinity. We also carried out a second HAE assay in the presence of zanamivir or oseltamivir. A weaker binding HA will enable virus to elute in higher concentrations of all NAIs compared with the wild-type. In contrast, NA mutations will enable the virus to elute only in the drug to which it is resistant.
Each of the viruses bound turkey RBCs, with a titre of 64 haemagglutinating units (Table 2 ). Both the control and ZP6 viruses eluted rapidly from turkey RBCs, with complete elution after 1 h at 378C. Elution was seen in the last well (1: 64) for the two ZO viruses, but also in the wells with the highest amount of virus. Elution at these higher concentrations of virus was presumably due to the additional NA activity of the excess non-agglutinated viruses. Even at high virus concentrations elution was still very slow. After 2 h the ZOP4 virus had eluted to 1:8 and the ZOP12 virus had only eluted to 1:2. Since the control virus eluted well this also suggested that lack of elution was due to reduced NA activity in both ZO viruses, with the double mutant having the lowest NA activity. This is consistent with the lower NA activity of the ZOP12 virus in the enzyme assay.
All viruses agglutinated chicken RBCs, but in contrast to the turkey RBCs there was a notable difference between the control and ZP6 virus for elution ( Table 2 ). The control virus only eluted at the highest virus concentrations at 1 :2 and 1 : 4 after 2 -4 h. No elution occurred in the dilute virus wells. In contrast, the ZP6 virus eluted rapidly and fully after 1 h at 378C, indicating that HA G158E reduced the affinity for the chicken RBCs compared with the wild-type HA. Elution of the ZOP4 virus was similar to the control, but the ZOP12 virus only eluted at 1 : 2, again consistent with lower NA activity.
Elution of the viruses in the presence of 2-fold dilutions of zanamivir or oseltamivir showed that both ZP6 and ZOP4 eluted in much higher concentrations of both NAIs compared with the control (Table 3 ). This would be consistent with reduced susceptibility due to HA G158E in the ZP6 and D198G in the ZOP4 viruses. The most dramatic effect was seen with the ZOP12 virus. D198G and H274Y acted synergistically, since this virus still eluted in 10 mM oseltamivir. There was no further decrease in susceptibility to zanamivir, consistent with no effect of the H274Y mutation.
Effects of mutations on growth in cell culture
Plaquing of the viruses in MDCK cells revealed that plaque sizes were comparable for both the control and ZP6 viruses, In vitro selection of resistant H1N1/09 viruses 1879 JAC 3 -4 mm at 4 days post-infection. Both the D198G and H274Y mutations had an adverse effect on virus spread, since both had reduced plaque sizes, 2 mm for ZOP4 and 1 mm for the ZOP12 double mutant. PRAs were therefore fixed at day 4 for the control and ZP6, but at day 6 for ZOP4 and ZOP12 viruses.
Since the NAIs prevent the spread of virus, relative susceptibility in a PRA is primarily determined by the drug concentration causing a 50% decrease in plaque size. At higher drug concentrations there is also a decrease in plaque number, but this is only generally used as a secondary measure. Based on a reduction in plaque size (Figure 1 ), ZP6 showed a 10-fold decrease in drug susceptibility to both inhibitors and also drug dependence, with more plaques in 1 and 10 nM for both inhibitors than in the control wells. Drug dependence is seen when the HA affinity is so low that the NA can cleave receptors before the virus can adsorb to the cells. 20 Decreasing NA activity by the addition of inhibitor enables the weakbinding HA to remain bound long enough to the cell for the virus to infect. Drug dependence of the ZP6 is consistent with the altered susceptibility being due to the HA G158E mutation and not the NA N146S mutation. 20, 31 There was also a small effect of the D198G on susceptibility to both inhibitors. The additional H274Y mutation enhanced oseltamivir resistance even further, with a 1000-fold reduction in susceptibility compared with the wild-type virus.
Growth kinetics of all viruses were determined in MDCK cells. Results in Figure 3 show that the rates of replication were comparable for all viruses, but the yields of each of the mutants were lower compared with the wild-type virus. This would be consistent with lower affinity of the HA of the ZP6 leading to lower efficiency of infection and reduced NA activity of both ZO viruses, resulting in decreased efficiency of elution and spread.
Enzyme kinetics
Some of our characterization indicated that the D198G and H274Y mutations resulted in reduced enzyme activity. To further understand the impacts of the NA mutations on the NA function we determined Michaelis -Menten constants, K m s, to compare the affinities of the enzymes for the MUNANA substrate.
We have previously shown that the H274Y mutation in our A/Mississippi/03/01 reference virus increased the IC 50 for oseltamivir by 800-fold, but only increased the K m by less than 2-fold compared with the wild-type virus (Table 1) . 19 Others also report a ,2-fold increase in K m with the H274Y mutation, including for a pandemic H1N1/09 NA. 32, 33 Hence our results ( Table 1 ) demonstrated unexpectedly that despite the minimal effect of N146S on drug susceptibility, it had a significant effect on the affinity for MUNANA, demonstrating a 2-fold higher K m . Furthermore, despite the relatively small effect of D198G on drug susceptibility, it reduced the affinity for MUNANA by almost 3-fold. The additional H274Y mutation in the ZOP12 NA further dramatically decreased the affinity for MUNANA compared with the single ZOP4 D198G NA.
We also determined the effects of the mutations on the K i for each of the inhibitors (Table 1) . Following a similar pattern to that observed with the IC 50 s, the K i s were marginally higher for the ZP6 virus with the N146S NA mutation compared with the wildtype, higher again for D198G ZOP4 and highest for the dual D198G and H274Y ZOP12 mutant.
Discussion
We passaged a swine pandemic H1N1/09 virus in increasing concentrations of zanamivir to determine whether we could force the selection of a virus with high-level resistance to zanamivir. We did select a virus that could grow in high concentrations of zanamivir; however, it had mutations in both the NA (N146S) and the HA (G158E; G155E H1 numbering). Enzyme assays demonstrated that the NA enzyme only had about a 2-fold reduction in susceptibility, but the HA mutation affected affinity and/or specificity of receptor binding. The virus eluted more rapidly from chicken RBCs compared with the wild-type virus and demonstrated both reduced drug susceptibility and drug dependence in the PRA in cell culture. It also grew to a lower titre than the wild-type virus in MDCK cells. It is well established that HA mutations can reduce drug susceptibility and confer drug dependence in vitro, 20, 30, 31, 34 although the clinical significance is still not clear. Residue G158 is near the HA receptor binding site residues W153 and T155. Mutations at T155 have been shown to confer both reduced NAI susceptibility and drug dependence in vitro. 20 There are reports of clinical isolates of H1N1/09 with both G158E and D222G mutations, 35, 36 although none with the single G158E has been analysed for drug susceptibility. The G158E (G155E H1 numbering) in pandemic H1N1/09 has been reported to increase yields of virus in eggs, as well as increasing plaque size in MDCK cells, 37 suggesting alteration in receptor binding affinity or specificity. Since this is the first report of G158E affecting drug susceptibility, we still have much to learn about the impacts of mutations on HA receptor binding.
The N146S NA mutation is at a highly conserved potential N-linked glycosylation site. 38 It is not one of the structural or McKimm-Breschkin et al.
functional amino acids involved in substrate or inhibitor binding and is more than 17 Å from the closest part of the ligand (Figure 4a ). Functional NA exists as a tetramer, with each monomer a box-shaped head structure attached to a slender stalk. Similar to other influenza NAs, in the wild-type N1 NA tetramer the N146 glycosylation sites for adjacent monomers are located at a close distance of 26 Å from each other on the top of the tetramer head. The carbohydrate chains extend outwards from the NA and virus surface. 39 It is not surprising that a mutation of N146S is reported to dramatically affect the folding and transport of recombinant N2 NA of A/Tokyo/3/67 to the cell surface with complete loss of enzyme activity. 40 In contrast, Abed et al. 41 reported that an N146K mutation in combination with S219T, A272V mutations and a four amino acid deletion (residues 245-248) in an H3N2 NA did not appear to alter drug susceptibility or enzyme activity. Although N146K would lead to loss of N-linked glycosylation, the lack of impact could be partially explained by a compensatory effect of lysine. Lysine is able to interact with saccharides, including N-acetyl glucosamine, resulting in non-enzymatic addition of a sugar (glycation). 42 The H1N1 WSN NA is also not normally glycosylated due to an arginine at 146. Rather than compromising its activity, a lack of the sugars is thought to contribute to its neurovirulence and ability to grow in a wider range of cells. 43, 44 However, similar to lysine, it is possible that the positively charged arginine could also be involved in compensatory non-enzymatic glycosylation of the protein. While the N146S NA mutation in the pandemic H1N1/09 ZP6 virus only had a minimal impact on drug susceptibility, unexpectedly, the mutation did have a large effect on affinity of the enzyme for the MUNANA substrate, with a 2-fold increase in K m . It is possible that loss of the carbohydrate side chain may affect folding of the enzyme, affecting its enzyme activity and interaction with infected cells, but with only a small impact on drug susceptibility.
In our passaging in the presence of both zanamivir (maintained at 10 times the IC 50 after P5) and increasing oseltamivir, we initially selected a virus with a D198G mutation (D199 N1 and D197 B numbering) at P4. This mutation reduced susceptibility to all NAIs. D198 is not a conserved residue among all influenza strains. In fact, sequence analysis shows that the wild-type N9 of the NWS/G70C we have used for our previous resistance studies has N198, but this does not confer reduced drug susceptibility. Viruses with either D198N or D198E have been previously detected in clinical isolates from patients with or without drug treatment, although interestingly primarily in influenza B isolates. 45 -49 D198N mutants have also been selected in vitro by passaging influenza B isolates in oseltamivir. 50 Passaging an H5N1 virus in vitro in the presence of zanamivir 51 selected for a D198G mutant virus. The D198G mutation reduced relative enzyme activity by 50% and the virus did not replicate as well in cell culture, consistent with our results. The effects on K m of mutations at D198 vary, from no effect with a conservative mutation D198E involving two negatively charged residues, a 1.5-fold increase in D198N 22 with a substitution to a polar residue, and a 2.8-fold increase with D198G resulting in loss of a side chain.
We have recently published the structure of an influenza B NA with a D198E mutation 22 and have shown that changes in D198 impact on interactions of R152 with the N-acetyl group on the substrate or inhibitor rings. Hence mutations at this site would impact on binding of all inhibitors and substrate, thus also possibly affecting enzyme activity (Figure 4b) .
While D198 mutations generally only confer a small reduction in susceptibility, what was of more concern here was that a double mutant with both D198G and H274Y was subsequently selected. In our assays NAs with an H274Y mutation usually have an IC 50 of 1000 -2000 nM for oseltamivir and 100 -200 for peramivir (Table 1) . 19 However, with the double mutants the IC 50 for oseltamivir was 14 000 nM and for peramivir was 1700 nM. Hence, as each of the mutations affects binding to different parts of the ligand or inhibitors, the dual mutations have a synergistic effect. Synergistic effects with dual mutations are also seen with H274Y and I222R, H274Y and I222V 52 and In vitro selection of resistant H1N1/09 viruses H274Y and I222M mutations. 51 Replacement of the positively charged histidine with the bulky aromatic tyrosine will affect the interactions between R224 and E276 ( Figure 4b) . 2 Additional mutations at the I222 site will further destabilize and change the protein fold around R224, affecting the drug binding pocket.
Emergence of such a highly resistant double mutant in a clinical isolate could result in failure of oseltamivir and peramivir treatment, although zanamivir would be expected to still be effective. However, both the D198G and the double mutant virus grew to lower titres in MDCK cells compared with the wild-type virus. The dual mutations resulted in reduced NA activity and reduced affinity for substrate compared with either the D198 or the H274Y mutation alone. 19, 33 Hence in vitro results suggest that these viruses may be compromised in their fitness. However, as with the seasonal H1N1 viruses, ultimately there may be adaptive mutations, which help maintain fitness of highly resistant viruses. 53 Thus, consistent with the clinical observations to date, selection of a pandemic H1N1/09 virus with an NA mutation conferring high-level resistance to zanamivir was not achieved. In addition, an oseltamivir-and peramivir-resistant virus with an H274Y mutation in addition to a D198G mutation emerged despite dual treatment with zanamivir and oseltamivir.
